OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis

Journal article

BACKGROUND: Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in children. METHODS: A decision tree model was used to estimate the cost and quality-adjusted life-years (QALYs) of OM-85 BV in a patient aged 1-6 with a history of recurrent respiratory tract infections. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost-effectiveness was evaluated using the willingness-to-pay defined for Colombia of US$5180 per QALY. The time horizon defined was six months. Costs were estimated from a societal perspective. RESULTS: The expected annual cost per patient with OM-85 BV was US$843 and with placebo was US$1167. The QALYs per person estimated with OM-85 BV was 0.91 and with placebo was 0.89. CONCLUSION: In conclusion, our study shows that OM-85 BV is a cost-effective strategy to reduce the incidence of recurrent respiratory tract infections in children. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines.

Authors: Buendía, JA; Patiño, DG; Lindarte, EF

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: BioMed Central
• Journal: BMC Pulmonary Medicine
• Volume: 22
• Issue: 1
• Pages: 465-465
• Article number: 465
• Publication date: 2022-12-06
• DOI: 10.1186/s12890-022-02264-9
• EISSN: 1471-2466
• ISSN: 1471-2466
• Language: English
• Keywords: Respiratory tract; Respiratory tract infections; Medicine; Intensive care medicine; Respiratory system; Internal medicine